Article Details
Retrieved on: 2021-06-14 16:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Michal Fresser, CEO of Axon Neuroscience, commented: "Our Phase II trial successfully demonstrated the strengths of our lead asset AADvac1, a tau ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here